Fragment-based virtual screening identifies a first-in-class preclinical drug candidate for Huntington's disease.
- DOI
- 10.1038/s41598-022-21900-2
- Published
- 2022 Nov 16
- Container
- Scientific reports
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41598-022-21900-2,
title = {Fragment-based virtual screening identifies a first-in-class preclinical drug candidate for Huntington's disease.},
author = {Galyan SM and Ewald CY and Jalencas X and Masrani S and Meral S and Mestres J},
year = {2022},
journal = {Scientific reports},
doi = {10.1038/s41598-022-21900-2},
url = {https://doi.org/10.1038/s41598-022-21900-2}
}RIS
TY - JOUR TI - Fragment-based virtual screening identifies a first-in-class preclinical drug candidate for Huntington's disease. AU - Galyan SM AU - Ewald CY AU - Jalencas X AU - Masrani S AU - Meral S AU - Mestres J PY - 2022 JO - Scientific reports DO - 10.1038/s41598-022-21900-2 UR - https://doi.org/10.1038/s41598-022-21900-2 ER -
APA
SM, G., CY, E., X, J., S, M., S, M., & J, M. (2022). Fragment-based virtual screening identifies a first-in-class preclinical drug candidate for Huntington's disease.. Scientific reports. https://doi.org/10.1038/s41598-022-21900-2
Source records
- pubmed · retrieved 2026-09-26T17:15:39.655Z